Hanheng Biotechnology (Shanghai) Co., Ltd.

About Us

Hanbio is a biotechnology company that specializes in the research, development, and production of biological products for scientific, medical, and industrial applications. It's great to know that Hanbio offers virus packaging, plasmid vector construction, and a wide range of reagents. These products are essential for many molecular biology and biotechnology applications, including gene transfer, gene expression studies, and the production of viral vectors for various research and therapeutic purposes.

98%+

Positive Feedback

8000+

User Citations

10000+

Client Projects Annual

10w+

Project experiences

About Us

In addition to its product offerings, Hanbio also provides technical support and expertise to its customers, aiming to assist researchers and scientists in achieving their experimental and diagnostic goals. The company's commitment to quality, innovation, and customer satisfaction has contributed to its reputation as a trusted provider of biological research tools and solutions.

About Us
Spirit
Spirit

Embrace challenges and move forward with resilience

Vision
Vision

Innovate in gene technology. Drive scientific milestones. Empower healthcare

Mission
Mission

Developing advanced, precise gene platforms and technologies. Delivering excellent solutions for pharmaceutical research and making outstanding contributions to global health

Service
Service

Committing to excellence in quality. Supporting scientific research wholeheartedly

Hanbio's History

Hanbio History
2010
2010
  • Established in Shanghai Zhangjiang High tech Park

  • Take the lead in developing autophagy double label virus products

2016
2016

Virus products are exported to North America and the Middle East

2017
2017

Becoming a high-tech enterprise in Shanghai

2019
2019

Introducing a new production management system, reducing customer complaint rate to less than 1%

2023
2023

Establish an innovative research and development center.

2025
2025

Goal: Listing 1-2 gene therapy AAV drugs with independent intellectual property rights